A phase 2 trial of Zynerba Pharmaceuticals’ Fragile X syndrome drug met its primary endpoint. The beleaguered biotech’s stock doubled on news of the route to redemption, despite the study’s lack of a ...
ANAVEX ® 2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address behavioral and cognitive deficits in individuals with ...
What would happen if hundreds of social scientists and data scientists worked together on a scientific challenge to improve the lives of disadvantaged children in the United States? The Fragile ...
Data to be Presented at the Hot Topics in Child Neurology Podium Presentation Session at the American Academy of Neurology Annual Meeting PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences ...
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results